NIR fluorescent substrate-driven discovery of prolyl endopeptidase natural inhibitors and its inhibition of alpha-synuclein aggregation and promotion of autophagy

Prolyl endopeptidase (PREP) drives neurodegenerative diseases through dual mechanisms involving enzymatic activity and protein-protein interactions (PPIs), yet current inhibitors predominantly target single pathways.

Prolyl endopeptidase (PREP) fuels neurodegeneration via enzymatic cleavage and pathological PPIs, yet current inhibitors usually target only one facet. In this study, leveraging our developed high-sensitivity and high-specificity near-infrared fluorescent probe Z-GP-ACM, we established and validated a screening platform for PREP inhibitors with mouse brain S9 instead of the human recombinant PREP.

Screening a library of 110 natural compounds identified a series of flavonoid derivatives (FV64-FV68) as potent PREP inhibitors, with FV67 and FV68 exhibiting particularly strong inhibition (IC₅₀ values of 0.65 μM and 0.31 μM, respectively). Reversibility assays revealed that all new inhibitors display time-independent potency (IC₅₀ unchanged after 5 vs 35 min pre-incubation), confirming reversible inhibition.

Furthermore. Kinetic analyses classified FV66/FV67 as mixed-type and FV64/FV65/FV68 as non-competitive inhibitors. Molecular docking simulations further revealed that FV68 binds the S1 and S2 sub-sites of PREP through hydrogen bonding and π-π stacking, which is the structural basis for its high activity. Further studies showed that both FV67 and FV68 inhibited PREP activity in HT22 and SH-SY5Y cells with a dose-dependent manner. Notably, FV68 enhanced autophagy, reduced α-synuclein aggregation, and mitigated H₂O₂-induced oxidative stress. These studies not only provide directions for the development of novel PREP inhibitors derived from natural products, also reveal new mechanisms by which natural compounds may intervene in neurodegenerative diseases by PREP-inhibited modulating PPIs.